Skip to main content

Table 2 Comparison between the preinjection and postinjection assessments regarding outcome measures among the two treatment groups

From: Efficacy of neural prolotherapy versus local corticosteroid soft tissue injection for treatment of chronic anserine bursitis: a prospective randomized clinical trial

Outcome measures

Group I (NP)

(n = 34 lower limbs obtained from 22 patients)

mean ± SD

Group II (CS)

(n = 33 lower limbs obtained from 21 patients)

mean ± SD

Test of significance§

P

WOMAC pain subscale

 Preinjection assessment

13.18 ± 3.78

10.95 ± 4.26

1.816

0.077

 Postinjection assessment

2.31 ± 2.58

1.71 ± 2.02

0.849

0.401

 Test of significance†

14.040

10.862

  

 P

≤ 0.0001*

≤ 0.0001*

  

WOMAC stiffness subscale

 Preinjection assessment

1.36 ± 0.78

1.28 ± 0.71

0.338

0.737

 Postinjection assessment

0.22 ± 0.42

0.19 ± 0.51

0.256

0.799

 Test of significance†

6.884

6.532

  

 P

≤ 0.0001*

≤ 0.0001*

  

WOMAC function subscale

 Preinjection assessment

25.13 ± 7.26

21.00 ± 7.94

1.783

0.082

 Postinjection assessment

4.68 ± 5.83

3.14 ± 4.04

1.001

0.323

 Test of significance†

13.838

11.971

  

 P

≤ 0.0001*

≤ 0.0001*

  

WOMAC total

 Preinjection assessment

39.68 ± 10.20

33.23 ± 11.75

1.922

0.062

 Postinjection assessment

7.09 ± 8.46

5.42 ± 7.54

0.679

0.501

 Test of significance†

16.048

11.387

  

 P

≤0.0001*

≤0.0001*

  

Overall AB pain severity (VAS)

 Preinjection assessment

8.76 ± 1.34

8.78 ± 1.45

− 0.068

0.946

 Postinjection assessment

1.52 ± 1.82

0.96 ± 1.49

1.371

0.175

 Test of significance†

20.773

23.105

  

 P

≤ 0.0001*

≤ 0.0001*

  

Patient’s global assessment of AB severity (VAS)

 Preinjection assessment

8.10 ± 1.38

8.54 ± 1.37

− 1.316

0.193

 Postinjection assessment

1.00 ± 1.37

0.81 ± 1.23

0.570

0.571

 Test of significance†

22.101

29.084

  

 P

≤ 0.0001*

≤ 0.0001*

  

Tenderness at the anserine bursa region

 Preinjection assessment‡

34 (100)

33 (100)

NA

NA

 Postinjection assessment‡

11 (32.4)

6 (18.2)

1.776||

0.262

  1. WOMAC Western Ontario McMasters Universities osteoarthritis index, AB anserine bursitis, VAS visual analogue scale, NP neural prolotherapy group, n number, SD standard deviation, CS corticosteroid group, NA not applicable
  2. *P is significant at < 0.05
  3. †Value of paired t-test
  4. ‡Data are represented as number (percentage) of lower limbs
  5. §Value of Student’s t-test
  6. ||Value of Chi-square test